Fewer than a tenth of patients eligible to benefit from GLP-1 drugs like Wegovy can access them, warns the WHO as it publishes its inaugural advice on the drugs.
With over a billion individuals worldwide currently obese, it is advocating for more widespread and fairer access to this class of drugs.
According to projections, in excess of 2,000,000,000 are projected to be obese by 2030 if no action is taken.
"Our latest guidance affirms that obesity is a long-term condition that can be treated with thorough and lifelong support," remarked the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and supply-chain constraints are key hurdles to universal access to the treatments that can assist patients in reducing significant body mass, explains the body.
GLP-1 Therapy Scarcity
Even in the current most favorable case, the supply of these medications could only cover approximately 100 million people – under 10% of those who need them, as stated by the WHO.
The recommendation urges nations and manufacturers to increase access, by measures like voluntary licensing.
Exclusive production rights on the active ingredient – the primary ingredient of a leading brand – is due to expire in several countries in 2026.
How Weight-Loss Jabs Operate
The injections imitate a natural hormone to slow digestion, reduce hunger and boost feelings of fullness so people consume fewer calories.
Individuals commonly see weight reduction after several weeks of starting on the regular doses.
Studies suggests people may see weight return after a year of discontinuing the drug, as their usual appetite come back.
Being above a healthy weight increases your likelihood for contracting diseases, including type 2 diabetes, cardiovascular issues, stroke, and specific cancers.
Obesity impacts individuals in all nations and was linked to millions of fatalities worldwide in 2024, according to the health agency.
